Über uns Aktuelle Projekte Publikationen Kooperationen Weiterbildung Anmeldungen Klassenraum Links

Aktuelle Projekte

Auf den folgenden Seiten können Sie sich einen Überblick über unsere umfassenden Pojekte verschaffen.

NN9924-4635

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes

I8H-MC-BDCP

A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy

I8H-MC-BDCL

A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus

I8F-MC-GPHD

A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) with or without Metformin

I6T-MC-AMAM

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

I8F-MC-GPGN

The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

LPS14947

A 12-week randomized controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitus

EX9536-4388

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

EX9924-4473

Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes

I8B-MC-ITSB

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes

K-877-302

Pemafibrate to reduce cardiovascular outcomes by reducing Triglycerides In patients with diabetes (PROMINENT)

H9X-MC-GBGC

A Randomized, Double-Blind Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus

Kooperationsprojekt

mit dem VDBD und der Universitätsklinik Jena
Entwicklung und Evaluation eines Schulungsprogramms für Angehörige von Menschen mit Diabetes mellitus (Finanzielle Förderung aufgrund eines Beschlusses des Bundestages durch die Bundesregierung).

abgeschlossene Studien:

QHD00011

Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older

EFC 14828

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk

I8F-MC-GPGI

A Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide versus Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or without Metformin (SURPASS-5)

EFC 14875

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

NN1436-4466

A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Basal Insulin Treated Subjects With Type 2 Diabetes Mellitus

NN9535-4386

Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes

NN1436-4465

A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in insulin-naïve subjects with type 2 diabetes mellitus

I8B-MC-ITRO

A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion

EFC 13794

A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone, followed by a ficed ratio combination single-arm 26-week etnsion period.

PRONTO-T2D

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D

PRONTO-T1D

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Arm, in Combination with Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes PRONTO-T1D

D5670C00004 MEDI 0382

A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 Diabetes Mellitus

EFC 15081

Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Period

D3250C00045

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI)

ESR-16-12160/UKE-DapEx-001

A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study)

NN9924-4224

Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52 - week randomised, double-blind, active-and placebo-controlled trial

NN9924-4221

A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

EFC 13794

A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone, followed by a ficed ratio combination single-arm 26-week etnsion period

EFC 13794

A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone, followed by a ficed ratio combination single-arm 26-week etnsion period

PRONTO-T2D

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D

PRONTO-T1D

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Arm, in Combination with Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes PRONTO-T1D

D5670C00004 MEDI 0382

A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 Diabetes Mellitus

EFC 15081

Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Period

D3250C00045

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI)

ESR-16-12160/UKE-DapEx-001

A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study)

NN9924-4224

Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52 - week randomised, double-blind, active-and placebo-controlled trial

NN9924-4221

A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

NN1218-4101

Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes

H9X-MC-GBGE

A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus

MB 102230

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus-Study Two

HOE901-EFC13470

A21-week, open-label, randomized,controlled, parallel-group, multi-center study evaluating the efficacy and safety of HOE901-U300 administered according to a device-supported treat-to-target regimen versus routine titration in T2DM patients

LPS14355

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with Type 1 or Type Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy

LPS 13931

Title: LPS13931 A twenty- six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo compared to standard of care insulin for initiating basal insulin in insulin naive patients with uncontrolled type 2 diabetes mellitus, with 6-month extension

LPS 14354

A Randomized, Open Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk with Non-HDL-C Not Adequately Controlled with Maximally Tolerated Statin Therapy

D589SC00003

A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budenoside/formoterol) Turbohaler 160/4,5 µg “as needed” compared with Pulmicort (budenoside) Turbohaler 0,4 mg “as needed”.

D1689C00014

A 52-week, multi-centre, randomised, parallel-group, double-blind, active-controlled, phase IV study to evaluate the safety and efficacy of Dapagliflozin or Dapagliflozin plus Saxagliptin compared with Sulfonylurea all given as add-on therapy to Metformin in adult patient with type 2 diabetes who have inadequate control on Metformin monotherapy

MB102-229

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus

Development and Evaluation

„Development and Evaluation of an evidence-based shared making programme for prevention of myocardial infarction in type 2 diabetes“ Projektleitung: Dr. phil. Matthias Lenz, Universität Hamburg, Fachbereich Gesundheitswissenschaften.
Laufzeit seit 2012

Diabetesversorung im ländlichen Raum

Ein Versorgungsforschungsprojekt zum Einfluss der Betreuung durch Diabetesberater in strukturschwachen Gebieten auf die Versorgungsqualität von Menschen mit Diabetes

NN9535-3744

A long-term, randomized, double-blind, placebo-controlled, multinational- multi-centre trial to evaluate cardiovascular and other long term outcomes with semaglutide in subjects with type 2 diabetes. Trial phase: 3a.
Laufzeit seit 2012

NN9535-3624

Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.
Laufzeit seit 2014

Liraglutide Effect and Action in Diabetes

LEADER™ (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results). Along-term, multicentre, international, randomised, double-blind, placebo-controlled, phase 3b trial - 2010

EFC13799 SENIOR

A randomized, open-label,2-arm parallel-group, multicenter, 26-week study assessing the safety and efficacy of HOE901-U300 versus Lantus in older patients with type 2 diabetes inadequately controlled on antidiabetic regimes either including no insulin, or with basal insulin as their only insulin

NN1218-3852

Onset1. Efficacy and safety of FiAsp compared to insulin aspart both in combination with insulin detemir in adults with type 1 diabetes.
Laufzeit seit 2013

CLCZ696B2314

Eine multizentrische, doppelt-blind, aktivkontrollierte Parallelgruppenstudie zur Untersuchung der Wirksamkeit und Verträglichkeit von LCZ696 gegenüber Enalapril in Hinblick auf Morbidität und Mortalität bei Patienten mit chronischer Herzinsuffizienz und reduzierter Ejektionsfraktion - Abgeschlossen seit 2014

CLAF237ADE08

A randomized study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic control on their current sulfonylurea monotherapy.
Abgeschlossen seit 2013

NN2211-3917

The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes. A 26-week double-blind placebo-controlled randomized multicentre, multinational parallel-group trial.
Abgeschlossen seit 2013

Effekte einer CPAP-Therapie

Hecht L., Effekte einer CPAP-Therapie auf Marker der Insulinresistenz und des Glukosestoffwechsels bei Patienten mit obstruktivem Schlafapnoesyndrom. Ein systematischer Review mit Metaanalyse, Diabetes und Stoffwechsel (1), 31, - 2010

Prävalenz gestörter Atmung im Schlaf

Prävalenz gestörter Atmung im Schlaf bei Patienten mit Beinvenenthrombose / Lungenembolie. Eine prospektive multizentrische Querschnittsuntersuchung der AG Kreislauf und Schlaf der DGSM - 2009

TRANS-North study

Phase III, double-blind, placebo controlled, parallel group, international, multicenter studie of 12 weeks treatment with trafermin 0,01% spray in patients with diabetic foot ulcer of neuropathic origin. 2011 - 2012